The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Exon 19 deletion association with progression-free survival compared to L858R mutation at exon 21 in treatment with first-line EGFR-TKIs: A meta-analysis of subgroup data from eight phase III randomized controlled trials.
Wenhua Liang
No relevant relationships to disclose
Jin Sheng
No relevant relationships to disclose
Xuan Wu
No relevant relationships to disclose
Yaxiong Zhang
No relevant relationships to disclose
Shiyang Kang
No relevant relationships to disclose
Li Zhang
Consultant or Advisory Role - AstraZeneca (U); Pfizer (U); Roche (U)
Honoraria - AstraZeneca; Lilly; Roche
Research Funding - AstraZeneca; Aventis; Roche